



UNIVERSITY OF LEEDS

This is a repository copy of *A Phase II Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-Positive Pathogens*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/119666/>

Version: Accepted Version

---

**Article:**

Huang, DB, File, TM, Torres, A et al. (5 more authors) (2017) A Phase II Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-Positive Pathogens. *Clinical Therapeutics*, 39 (8). pp. 1706-1718. ISSN 0149-2918

<https://doi.org/10.1016/j.clinthera.2017.07.007>

---

© 2017 Elsevier Inc. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

1 Table 4: Safety Parameters by Treatment

Category	Iclaprim q12h (N=23)	Iclaprim q8h (N=24)	Vancomycin (N=23)
Death within 28 days from start of treatment	2 (8.7%)	3 (12.5%)	5 (21.7%)
Any drug-related TEAE	4 (17.4%)	3(12.5%)	7 (30.4%)
Any serious AE	5 (21.7%)	4 (16.7%)	10 (43.5%)
Discontinued medication due to AEs	0 (0.0%)	2 (8.3%)	3 (13.0%)
TEAE $\geq$ 12 in any treatment arm assessed as related to study medication			
Thrombocythemia	0	1 (4.2%)	2 (8.7%)
<u>Sick sinus syndrome</u>	<u>0</u>	<u>0</u>	<u>1 (4.3%)</u>
<u>Aphthous stomatitis</u>	<u>0</u>	<u>1 (4.2%)</u>	<u>0</u>
Diarrhea	0	0	2 (8.7%)
<u>Candidiasis</u>	<u>1 (4.3%)</u>	<u>0</u>	<u>0</u>
<u>Alanine aminotransferase increased</u>	<u>0</u>	<u>0</u>	<u>1 (4.3%)</u>
<u>Aspartate aminotransferase increased</u>	<u>0</u>	<u>0</u>	<u>1 (4.3%)</u>
<u>Blood alkaline phosphatase increased</u>	<u>0</u>	<u>0</u>	<u>1 (4.3%)</u>
<u>Blood creatinine increased</u>	<u>0</u>	<u>0</u>	<u>1 (4.3%)</u>
<u>Blood urea nitrogen increased</u>	<u>0</u>	<u>0</u>	<u>1 (4.3%)</u>
<u>Prolonged QTc</u>	<u>2 (8.7%)</u>	<u>0</u>	<u>0</u>
<u>Liver function test abnormal</u>	<u>0</u>	<u>0</u>	<u>1 (4.3%)</u>
<u>Anorexia</u>	<u>1 (4.3%)</u>	<u>0</u>	<u>0</u>
<u>Dizziness</u>	<u>1 (4.3%)</u>	<u>0</u>	<u>0</u>

<u>Chronic Obstructive pulmonary disease</u>	<u>0</u>	<u>1 (4.2%)</u>	<u>0</u>
<u>Rash</u>	<u>0</u>	<u>1 (4.2%)</u>	<u>0</u>

2

3 TEAE=treatment emergent adverse event; AE= Adverse event; N=Total number of patients in

4 the population; SAE=serious adverse event